JP2015534819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534819A5 JP2015534819A5 JP2015540872A JP2015540872A JP2015534819A5 JP 2015534819 A5 JP2015534819 A5 JP 2015534819A5 JP 2015540872 A JP2015540872 A JP 2015540872A JP 2015540872 A JP2015540872 A JP 2015540872A JP 2015534819 A5 JP2015534819 A5 JP 2015534819A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- nucleic acid
- genetically modified
- promoter
- acid encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 24
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 102000004889 Interleukin-6 Human genes 0.000 claims description 22
- 201000005787 hematologic cancer Diseases 0.000 claims description 22
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 22
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 20
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 102000052611 human IL6 Human genes 0.000 claims description 13
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 12
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 12
- 101150036449 SIRPA gene Proteins 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000004083 survival effect Effects 0.000 claims description 7
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 6
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims description 6
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims description 6
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 claims description 6
- 102000000646 Interleukin-3 Human genes 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 101710113649 Thyroid peroxidase Proteins 0.000 claims description 6
- 102000046157 human CSF2 Human genes 0.000 claims description 6
- 102000055276 human IL3 Human genes 0.000 claims description 6
- 102000053400 human TPO Human genes 0.000 claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 230000011712 cell development Effects 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 13
- 102000025171 antigen binding proteins Human genes 0.000 claims 7
- 108091000831 antigen binding proteins Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 210000005260 human cell Anatomy 0.000 claims 6
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 claims 4
- 241000699670 Mus sp. Species 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 210000000952 spleen Anatomy 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000003209 gene knockout Methods 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722437P | 2012-11-05 | 2012-11-05 | |
| US61/722,437 | 2012-11-05 | ||
| PCT/US2013/068569 WO2014071397A2 (en) | 2012-11-05 | 2013-11-05 | Genetically modified non-human animals and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194712A Division JP6772234B2 (ja) | 2012-11-05 | 2018-10-16 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534819A JP2015534819A (ja) | 2015-12-07 |
| JP2015534819A5 true JP2015534819A5 (enExample) | 2016-12-22 |
| JP6422441B2 JP6422441B2 (ja) | 2018-11-14 |
Family
ID=49876957
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540872A Active JP6422441B2 (ja) | 2012-11-05 | 2013-11-05 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2018194712A Active JP6772234B2 (ja) | 2012-11-05 | 2018-10-16 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2020165884A Active JP7105844B2 (ja) | 2012-11-05 | 2020-09-30 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2022111649A Active JP7579304B2 (ja) | 2012-11-05 | 2022-07-12 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2024187836A Pending JP2025010204A (ja) | 2012-11-05 | 2024-10-25 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194712A Active JP6772234B2 (ja) | 2012-11-05 | 2018-10-16 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2020165884A Active JP7105844B2 (ja) | 2012-11-05 | 2020-09-30 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2022111649A Active JP7579304B2 (ja) | 2012-11-05 | 2022-07-12 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2024187836A Pending JP2025010204A (ja) | 2012-11-05 | 2024-10-25 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9901082B2 (enExample) |
| EP (5) | EP3556206B1 (enExample) |
| JP (5) | JP6422441B2 (enExample) |
| KR (5) | KR102275412B1 (enExample) |
| CN (3) | CN104918483B (enExample) |
| AU (3) | AU2013337242B2 (enExample) |
| CA (1) | CA2887706C (enExample) |
| DK (5) | DK4389764T3 (enExample) |
| ES (4) | ES2884598T3 (enExample) |
| FI (2) | FI3939423T3 (enExample) |
| IL (5) | IL299887B2 (enExample) |
| MX (3) | MX377561B (enExample) |
| MY (1) | MY175400A (enExample) |
| NO (1) | NO2946162T3 (enExample) |
| NZ (3) | NZ631614A (enExample) |
| PT (4) | PT3556206T (enExample) |
| RU (1) | RU2673156C2 (enExample) |
| SG (2) | SG11201502685XA (enExample) |
| WO (1) | WO2014071397A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| IN2015DN02032A (enExample) * | 2012-09-07 | 2015-08-14 | Univ Yale | |
| ES2884598T3 (es) | 2012-11-05 | 2021-12-10 | Regeneron Pharma | Animales no humanos modificados genéticamente y métodos de uso de los mismos |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| CA2900824A1 (en) | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| MX368931B (es) | 2013-09-23 | 2019-10-22 | Regeneron Pharma | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. |
| AU2014337526B2 (en) | 2013-10-15 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Humanized IL-15 animals |
| US20150143558A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| BR112016011004A2 (pt) | 2013-11-19 | 2017-12-05 | Regeneron Pharma | animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo |
| RU2700484C2 (ru) | 2014-04-08 | 2019-09-17 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы |
| US20160029604A1 (en) | 2014-04-28 | 2016-02-04 | Recombinetics, Inc. | Multiplex gene editing |
| CN106659146B (zh) | 2014-05-05 | 2020-06-23 | 再生元制药公司 | 人源化c5和c3动物 |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| PT3482629T (pt) * | 2014-05-19 | 2021-02-18 | Univ Yale | Animais não humanos geneticamente modificados que expressam epo humana |
| EP3683238A1 (en) | 2014-06-19 | 2020-07-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| KR102659123B1 (ko) | 2014-11-24 | 2024-04-22 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 cd3 복합체를 발현하는 비인간 동물 |
| FI3850946T3 (fi) * | 2014-12-05 | 2023-12-28 | Regeneron Pharma | Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni |
| EP3808775B1 (en) | 2014-12-09 | 2024-04-17 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| WO2016137841A1 (en) * | 2015-02-26 | 2016-09-01 | William Paterson University Of New Jersey | Transgenic mice |
| RU2732628C2 (ru) | 2015-04-06 | 2020-09-21 | Регенерон Фармасьютикалз, Инк. | Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных |
| PT3282835T (pt) * | 2015-04-13 | 2023-07-25 | Univ Yale | Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos |
| KR102454546B1 (ko) | 2015-11-20 | 2022-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물 |
| EP3895529B1 (en) | 2016-02-29 | 2026-04-29 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| JP7134944B2 (ja) * | 2016-08-11 | 2022-09-12 | ザ ジャクソン ラボラトリー | 遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US20190320633A1 (en) * | 2016-11-30 | 2019-10-24 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
| CN110461146A (zh) * | 2017-02-27 | 2019-11-15 | 再生元制药公司 | 视网膜劈裂的非人类动物模型 |
| CN107115424B (zh) * | 2017-05-09 | 2018-05-29 | 江西樟树市正康医药生物科技有限公司 | 改变酸性体质保钙及清热解毒的中药组合物及制备方法 |
| RU2019140867A (ru) | 2017-05-12 | 2021-06-15 | Зе Джексон Лаборатори | Nsg мыши, не имеющие mhc класса i и класса ii |
| JP7139419B2 (ja) | 2017-09-29 | 2022-09-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｔｒ遺伝子座を含む非ヒト動物および使用方法 |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| IL274740B2 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
| EP3768314A4 (en) | 2018-03-21 | 2022-01-05 | ALX Oncology Inc. | ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE |
| WO2019190990A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| IL315703A (en) | 2018-07-16 | 2024-11-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020074005A1 (en) * | 2018-10-12 | 2020-04-16 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric genes |
| CN111172190B (zh) * | 2018-12-25 | 2021-07-30 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子csf2基因改造非人动物的构建方法及应用 |
| ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| CA3137764A1 (en) | 2019-06-07 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
| WO2021011853A2 (en) * | 2019-07-17 | 2021-01-21 | Yale University | Genetically modified non-human animals and methods of use thereof |
| CN111304246B (zh) * | 2019-12-17 | 2021-05-04 | 百奥赛图江苏基因生物技术有限公司 | 一种人源化细胞因子动物模型、制备方法及应用 |
| US20230072216A1 (en) * | 2020-01-10 | 2023-03-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric mhc protein complex |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| KR20230074758A (ko) | 2020-09-24 | 2023-05-31 | 더 잭슨 래보라토리 | 면역 세포 요법을 평가하기 위한 인간화 마우스 모델 |
| US12376573B2 (en) | 2021-03-31 | 2025-08-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire |
| CN116918766A (zh) * | 2022-04-07 | 2023-10-24 | 上海立迪生物技术股份有限公司 | 一种人aml小鼠原位pdox模型的建立方法及应用 |
| CN116918767A (zh) * | 2022-04-07 | 2023-10-24 | 上海立迪生物技术股份有限公司 | 一种人all小鼠原位pdox模型的建立方法及应用 |
| AU2023310163A1 (en) | 2022-07-19 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Genetically modified animal model and its use to model the human immune system |
| IL325100A (en) | 2023-06-16 | 2026-02-01 | Regeneron Pharma | Vectors, genetically modified cells and genetically modified non-human animals containing them |
| WO2025171307A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) * | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
| WO2026096736A1 (en) | 2024-10-31 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Rodents expressing humanized polymeric immunoglobulin receptor |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5573930A (en) | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
| WO1988003173A2 (en) | 1986-10-24 | 1988-05-05 | Cetus Corporation | New forms of colony stimulating factor-1 |
| DE3853201T2 (de) | 1987-12-23 | 1995-09-14 | Univ Leland Stanford Junior | Schimäre immunkompromittierende Säugetiere und ihre Verwendung. |
| JP2981486B2 (ja) | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | 哺乳動物の免疫系研究方法 |
| JP2935511B2 (ja) * | 1989-10-20 | 1999-08-16 | 忠三 岸本 | ヒトｉｌ―６レセプターの製造方法 |
| US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
| DE69131331T2 (de) | 1990-01-15 | 2000-03-02 | Yeda Research And Development Co., Ltd. | Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren |
| DK0481058T3 (da) | 1990-05-03 | 1996-12-02 | Systemix Inc | Humant, lymfatisk væv i en immunokompromitteret vært |
| JPH05500617A (ja) | 1990-05-25 | 1993-02-12 | システミックス，インコーポレイティド | 免疫処理された宿主におけるヒト末梢血液細胞 |
| US5633426A (en) | 1990-05-25 | 1997-05-27 | Systemix, Inc. | In vivo use of human bone marrow for investigation and production |
| CA2103705C (en) | 1991-02-11 | 1996-01-30 | Ayub K. Ommaya | Spinal fluid driven artificial organ |
| US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
| EP0517199A1 (en) | 1991-06-04 | 1992-12-09 | Yeda Research And Development Company, Ltd. | Durable engraftment of human tissue and cells in normal mammals |
| WO1993005796A1 (en) | 1991-09-19 | 1993-04-01 | The Scripps Research Institute | Method for producing human antibodies in a non-human animal, and animals therefor |
| DE69229254T2 (de) | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co. Ltd., Tokio/Tokyo | Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper |
| US6353150B1 (en) | 1991-11-22 | 2002-03-05 | Hsc Research And Development Limited Partnership | Chimeric mammals with human hematopoietic cells |
| WO1993018144A1 (en) | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
| US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| US6018096A (en) | 1993-05-03 | 2000-01-25 | Surrogen, Inc. | Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells |
| US5663481A (en) | 1993-08-06 | 1997-09-02 | Mount Sinai Hospital Corporation | Animal model of the human immune system |
| JPH10503092A (ja) | 1994-07-27 | 1998-03-24 | メルク エンド カンパニー インコーポレーテッド | ブラジキニンｂ２受容体が改変されたトランスジェニック非ヒト動物 |
| US6455756B1 (en) | 1994-08-12 | 2002-09-24 | Novartis Ag | Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice |
| US7273753B2 (en) | 1996-08-02 | 2007-09-25 | Center Of Blood Research | Purification and uses of dendritic cells and monocytes |
| US6248721B1 (en) | 1997-04-09 | 2001-06-19 | Lung-Ji Chang | Method of using mouse model for evaluation of HIV vaccines |
| EP0973381B1 (en) | 1997-04-09 | 2010-03-03 | AMDL, Inc. | Animal model for evaluation of vaccines |
| GB2337755B (en) * | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| US20030028911A1 (en) | 1999-08-31 | 2003-02-06 | Manley Huang | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| JP2003508038A (ja) | 1999-08-31 | 2003-03-04 | ジェネンコア インターナショナル インコーポレーテッド | ドナー特異的機能性免疫の産生を容易にすることができるトランスジェニック哺乳類 |
| EP1244807A1 (en) | 1999-12-09 | 2002-10-02 | Human Genome Sciences, Inc. | Il-6 like polynucleotide |
| AU2001290855A1 (en) | 2000-09-14 | 2002-03-26 | Genetrol Biotherapeutics, Inc. | Method and cell composition for screening compounds for anti-inflammatory activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1553963A (zh) * | 2001-07-10 | 2004-12-08 | ǿ����ǿ���о�����˾ | 用于遗传修饰造血祖细胞的方法和这些被修饰细胞的应用 |
| WO2003039232A2 (en) * | 2001-10-26 | 2003-05-15 | Large Scale Biology Corporation | Endothelial cell derived hemotopoietic growth factor |
| WO2003041495A1 (en) | 2001-11-15 | 2003-05-22 | Kirin Beer Kabushiki Kaisha | Chimeric nonhuman animal |
| AU2003281309A1 (en) | 2002-07-05 | 2004-01-23 | Kirin Beer Kabushiki Kaisha | Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like |
| CN101250553A (zh) | 2002-07-13 | 2008-08-27 | 上海医学遗传研究所 | 一种促人血小板生成素表达载体及其构建方法 |
| AU2003278790A1 (en) | 2002-09-09 | 2004-03-29 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
| EP1418185A1 (en) | 2002-11-11 | 2004-05-12 | Aventis Pharma Deutschland GmbH | Use of EDG2 receptor in an animal model of heart failure |
| JP2006517096A (ja) | 2002-12-16 | 2006-07-20 | ジェネンテック・インコーポレーテッド | ヒトｃｄ２０を発現するトランスジェニックマウス |
| AU2004219592C1 (en) * | 2003-03-12 | 2011-02-24 | Genentech, Inc. | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| US20080311095A1 (en) | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| WO2006044962A1 (en) | 2004-10-19 | 2006-04-27 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| PL2019683T5 (pl) | 2006-04-25 | 2022-12-05 | The Regents Of The University Of California | Podawanie czynników wzrostu do leczenia zaburzeń OUN |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| US20080081064A1 (en) | 2006-09-28 | 2008-04-03 | Surmodics, Inc. | Implantable Medical Device with Apertures for Delivery of Bioactive Agents |
| EP2088854A1 (en) | 2006-12-05 | 2009-08-19 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Improved xenogenic immune system in a non-human mammal |
| GB0718029D0 (en) | 2007-09-14 | 2007-10-24 | Iti Scotland Ltd | Two step cluster deletion and humanisation |
| WO2009042917A1 (en) | 2007-09-28 | 2009-04-02 | The General Hospital Corporation | Methods and compositions for antibody production |
| WO2009097468A2 (en) | 2008-01-29 | 2009-08-06 | Kliman Gilbert H | Drug delivery devices, kits and methods therefor |
| KR20120088542A (ko) * | 2009-04-13 | 2012-08-08 | 아프세스 게엠베하 & 씨오. 카게 | 종양 치료를 위한 조작된 중간엽 줄기세포 및 이를 사용하는 방법 |
| SG176118A1 (en) * | 2009-06-29 | 2011-12-29 | Qingfeng Chen | Methods of producing humanized non-human mammals |
| JP2012531894A (ja) | 2009-06-29 | 2012-12-13 | レスコフ，イリヤ，ビー． | ヒト血液癌の非ヒト哺乳動物モデル |
| RU2425880C2 (ru) | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| NO2516457T3 (enExample) * | 2009-12-21 | 2018-08-11 | ||
| US9402377B2 (en) | 2010-09-20 | 2016-08-02 | Yale University | Human SIRPAalpha transgenic animals and their methods of use |
| WO2012051572A1 (en) | 2010-10-15 | 2012-04-19 | Massachusetts Institute Of Technology | A humanized non-human mammal model of malaria and uses thereof |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| PL2818478T3 (pl) * | 2011-10-28 | 2017-09-29 | Regeneron Pharmaceuticals, Inc. | Humanizowane il-6 i receptor il-6 |
| IN2015DN02032A (enExample) | 2012-09-07 | 2015-08-14 | Univ Yale | |
| ES2884598T3 (es) | 2012-11-05 | 2021-12-10 | Regeneron Pharma | Animales no humanos modificados genéticamente y métodos de uso de los mismos |
| MX368931B (es) | 2013-09-23 | 2019-10-22 | Regeneron Pharma | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. |
| AU2014337526B2 (en) | 2013-10-15 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Humanized IL-15 animals |
| PT3482629T (pt) | 2014-05-19 | 2021-02-18 | Univ Yale | Animais não humanos geneticamente modificados que expressam epo humana |
| PT3282835T (pt) | 2015-04-13 | 2023-07-25 | Univ Yale | Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos |
-
2013
- 2013-11-05 ES ES19176252T patent/ES2884598T3/es active Active
- 2013-11-05 IL IL299887A patent/IL299887B2/en unknown
- 2013-11-05 MY MYPI2015000877A patent/MY175400A/en unknown
- 2013-11-05 KR KR1020157011974A patent/KR102275412B1/ko active Active
- 2013-11-05 WO PCT/US2013/068569 patent/WO2014071397A2/en not_active Ceased
- 2013-11-05 CN CN201380056429.6A patent/CN104918483B/zh active Active
- 2013-11-05 DK DK24161280.3T patent/DK4389764T3/da active
- 2013-11-05 RU RU2015121195A patent/RU2673156C2/ru active
- 2013-11-05 IL IL311744A patent/IL311744B2/en unknown
- 2013-11-05 CN CN202210388378.8A patent/CN114766432B/zh active Active
- 2013-11-05 KR KR1020247008928A patent/KR102768101B1/ko active Active
- 2013-11-05 FI FIEP21176673.8T patent/FI3939423T3/fi active
- 2013-11-05 JP JP2015540872A patent/JP6422441B2/ja active Active
- 2013-11-05 NZ NZ631614A patent/NZ631614A/en unknown
- 2013-11-05 EP EP19176252.5A patent/EP3556206B1/en active Active
- 2013-11-05 DK DK17184813.8T patent/DK3308641T3/da active
- 2013-11-05 PT PT191762525T patent/PT3556206T/pt unknown
- 2013-11-05 SG SG11201502685XA patent/SG11201502685XA/en unknown
- 2013-11-05 PT PT171848138T patent/PT3308641T/pt unknown
- 2013-11-05 EP EP13811637.1A patent/EP2914102B1/en active Active
- 2013-11-05 ES ES13811637.1T patent/ES2655442T3/es active Active
- 2013-11-05 ES ES21176673T patent/ES2983031T3/es active Active
- 2013-11-05 EP EP24161280.3A patent/EP4389764B1/en active Active
- 2013-11-05 MX MX2019015882A patent/MX377561B/es active IP Right Grant
- 2013-11-05 KR KR1020217020816A patent/KR102402806B1/ko active Active
- 2013-11-05 CN CN201810319216.2A patent/CN108401987B/zh active Active
- 2013-11-05 US US14/072,626 patent/US9901082B2/en active Active
- 2013-11-05 KR KR1020227036338A patent/KR102649893B1/ko active Active
- 2013-11-05 DK DK21176673.8T patent/DK3939423T3/da active
- 2013-11-05 PT PT211766738T patent/PT3939423T/pt unknown
- 2013-11-05 DK DK19176252.5T patent/DK3556206T3/da active
- 2013-11-05 SG SG10201707449TA patent/SG10201707449TA/en unknown
- 2013-11-05 AU AU2013337242A patent/AU2013337242B2/en active Active
- 2013-11-05 EP EP17184813.8A patent/EP3308641B1/en active Active
- 2013-11-05 FI FIEP24161280.3T patent/FI4389764T3/fi active
- 2013-11-05 MX MX2015005654A patent/MX370856B/es active IP Right Grant
- 2013-11-05 EP EP21176673.8A patent/EP3939423B1/en active Active
- 2013-11-05 PT PT138116371T patent/PT2914102T/pt unknown
- 2013-11-05 DK DK13811637.1T patent/DK2914102T3/en active
- 2013-11-05 KR KR1020227017372A patent/KR102458016B1/ko active Active
- 2013-11-05 NZ NZ724353A patent/NZ724353A/en unknown
- 2013-11-05 CA CA2887706A patent/CA2887706C/en active Active
- 2013-11-05 NZ NZ749626A patent/NZ749626A/en unknown
- 2013-11-05 ES ES17184813T patent/ES2748662T3/es active Active
-
2014
- 2014-02-18 NO NO14705284A patent/NO2946162T3/no unknown
-
2015
- 2015-04-27 IL IL238478A patent/IL238478B/en active IP Right Grant
- 2015-05-04 MX MX2020012427A patent/MX2020012427A/es unknown
-
2016
- 2016-06-24 US US15/192,903 patent/US9986724B2/en active Active
-
2017
- 2017-11-06 US US15/804,989 patent/US10785968B2/en active Active
-
2018
- 2018-04-26 IL IL25896818A patent/IL258968B/en active IP Right Grant
- 2018-10-16 JP JP2018194712A patent/JP6772234B2/ja active Active
-
2019
- 2019-07-03 AU AU2019204775A patent/AU2019204775B2/en active Active
- 2019-10-23 IL IL270124A patent/IL270124B2/en unknown
-
2020
- 2020-08-21 US US17/000,140 patent/US11778995B2/en active Active
- 2020-09-30 JP JP2020165884A patent/JP7105844B2/ja active Active
-
2022
- 2022-01-18 AU AU2022200302A patent/AU2022200302B2/en active Active
- 2022-07-12 JP JP2022111649A patent/JP7579304B2/ja active Active
-
2023
- 2023-08-21 US US18/236,218 patent/US20240099278A1/en active Pending
-
2024
- 2024-10-25 JP JP2024187836A patent/JP2025010204A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shultz et al. | Humanized mice for immune system investigation: progress, promise and challenges | |
| Pham et al. | Preclinical models of pancreatic ductal adenocarcinoma and their utility in immunotherapy studies | |
| Dawson et al. | Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells | |
| Das et al. | Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice | |
| FI3939423T3 (fi) | Geneettisesti muokattuja ei-ihmiseläimiä ja niiden käyttömenetelmiä | |
| JP2022105531A (ja) | 遺伝学的に修飾された非ヒト動物およびその使用法 | |
| Karnik et al. | Emerging preclinical applications of humanized mouse models in the discovery and validation of novel immunotherapeutics and their mechanisms of action for improved cancer treatment | |
| JP2018500012A5 (enExample) | ||
| JP2014110814A5 (enExample) | ||
| JP2012532598A5 (enExample) | ||
| US20150007357A1 (en) | Use Of Humanized Mice To Determine Toxicity | |
| Kumari et al. | Humanized mouse models for immuno‐oncology drug discovery | |
| Dhenni et al. | Macrophages direct location-dependent recall of B cell memory to vaccination | |
| Chung et al. | Co-transplantation of human fetal thymus, bone and CD34+ cells into young adult immunodeficient NOD/SCID IL2Rγnull mice optimizes humanized mice that mount adaptive antibody responses | |
| Ren et al. | Translational models in glioma immunotherapy research | |
| Spits | New models of human immunity | |
| JP2025503669A (ja) | 改変されたｔ細胞を組み込むシステム及び方法 | |
| WO2022248445A1 (en) | Animal models and therapeutic molecules | |
| US11913026B2 (en) | Bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibodies, methods for production thereof and methods of treatment | |
| Yanagawa et al. | Development of a humanized mouse model to analyze antibodies specific for human leukocyte antigen (HLA) | |
| Chung et al. | Transplantation of human spleen into immunodeficient NOD/SCID IL2Rγnull mice generates humanized mice that improve functional B cell development | |
| Schardt et al. | IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release | |
| CN119384222A (zh) | 动物模型和治疗分子 | |
| Tanner et al. | Development of human B cells and antibodies following human hematopoietic stem cell transplantation to Rag2−/− γc−/− mice | |
| Chupp | Gneration of Humanized Immune System Mice Supporting Class-Switched, Hypermutated and Neutralizing Antibody Responses |